Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of ARO-DUX4 in participants with facioscapulohumeral muscular dystrophy Type 1 (FSHD1). In Part 1 of the study, participants will receive a single dose of ARO-DUX4 or placebo. In Part 2 of the study, participants will receive 2 or 4 doses of ARO-DUX4 or placebo. Participants who complete Part 1 will have the option to re-screen and re-randomize into Part 2. All participants will undergo pre- and post-dose MRI-guided muscle biopsies (a total of 2 biopsies). Participants who complete Part 1 and enroll in Part 2 will be required to undergo an additional screening biopsy. Participants completing Part 1 or Part 2 may have the option to continue to receive drug in an open-label extension study or may be eligible to participate in later-stage clinical studies.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06131983
Study type Interventional
Source Arrowhead Pharmaceuticals
Contact Medical Monitor
Phone 626-304-3400
Email ARO_DUX4@arrowheadpharma.com
Status Recruiting
Phase Phase 1
Start date February 26, 2024
Completion date June 2025

See also
  Status Clinical Trial Phase
Completed NCT02948244 - Effect of Creatine Monohydrate on Functional Muscle Strength in Children With FSHD N/A
Completed NCT05022355 - Examination of Operative Approach in pwFSHD (Patient With Facioscapulohumeral Muscular Dystrophy)
Recruiting NCT06096441 - FSHD Molecular Characterization
Completed NCT04377217 - Computerized Facial Recognition for Automated Diagnosis of the Facio-Scapulo-Humeral Muscular Dystrophy (FSMHD) N/A
Completed NCT05239520 - Understanding Control and Mechanisms of Shoulder Instability in FSHD
Recruiting NCT06378203 - Rehabilitation in Muscular Dystrophies From the Hospital Facility to the Home: Pilot Project [RIMUDI] N/A
Recruiting NCT05747924 - Phase 1/2 Study of AOC 1020 in Adults With Facioscapulohumeral Muscular Dystrophy (FSHD) Phase 1/Phase 2